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Editor: Chennai Guest EditorGenetic studies have thus far identiﬁed a limited number of loci associatedwith human longevity by applying age
at death or survival up to advanced ages as phenotype. As an alternative approach, one could ﬁrst try to identify
biomarkers of healthy ageing and the genetic variants associated with these traits and subsequently determine
the association of these variants with human longevity. In the present study, we used this approach by testing
whether the 35 baseline serum parameters measured in the Leiden Longevity Study (LLS) meet the proposed
criteria for a biomarker of healthy ageing.
The LLS consists of 421 families with long-lived siblings of European descent, who were recruited together with
their offspring and the spouses of the offspring (controls). To test the four criteria for a biomarker of healthy age-
ing in the LLS, we determined the association of the serum parameters with chronological age, familial longevity,
general practitioner-reported general health, and mortality.
Out of the 35 serumparameters, we identiﬁed glucose, insulin, and triglycerides as biomarkers of healthy ageing,
meeting all four criteria in the LLS.We subsequently showed that the genetic variants previously associatedwith
these parameters are signiﬁcantly enriched in the largest genome-wide association study for human longevity.
In conclusion, we showed that biomarkers of healthy ageing can be used to leverage genetic studies into human
longevity. We identiﬁed several genetic variants inﬂuencing the variation in glucose, insulin and triglycerides
that contribute to human longevity.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Biomarkers
Healthy ageing
Human longevity
Genetics1. Introduction
Chronological age is the main risk factor for many diseases. Howev-
er, the rate of ageing is different between persons and some individuals
becomevery old and seem to delay or even escape age-related disability
(Christensen et al., 2008; Terry et al., 2008). Hence, by investigating lon-
gevity as a trait, we may be able to identify mechanisms that promote
healthy ageing and protect against age-related disease. Since human
longevity is heritable and clusters in families (Perls et al., 2000;enter, Molecular Epidemiology
hovenweg 20, 2333 ZC Leiden,
, E.B.van_den_Akker@lumc.nl
van_Heemst@lumc.nl (D. van
om@lumc.nl (P.E. Slagboom),
. This is an open access article underWestendorp et al., 2009), genetic determinants of healthy ageing have
been investigated using genome-wide association studies (GWAS).
Thus far, only a limited number of longevity loci have been identiﬁed,
i.e. TOMM40/APOE/APOC1, FOXO3A and chromosome 5q33.3 (Broer
et al., 2015; Deelen et al., 2014a). Together, these loci only explain a
small part of the heritability of human longevity, which has been esti-
mated to be around 25% (Herskind et al., 1996; Hjelmborg et al.,
2006) and is assumed to be explained by many genes with relatively
small effects (Finch and Tanzi, 1997; Kirkwood et al., 2011). The lack
of identiﬁed loci is most likely caused by the small sample size of the
GWAS, which is attributable to limited availability of the studied out-
comes, i.e. prospective survival or survival up to advanced ages, i.e.
above 90 or 100 years (exceptional longevity).
As an alternative approach, one could ﬁrst try to identify biomarkers
of healthy ageing (Sprott, 2010) and the genetic variants associated
with these traits and subsequently determine the association of these
variants with longevity. We have previously proposed four criteria for
a quantitative parameter that, we think, need to be fulﬁlled beforethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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short, a biomarker of healthy ageing should show an association with
(1) chronological age, (2) familial propensity for longevity, (3) known
health parameters, and (4) morbidity and/or mortality (Box 1). Thus
far, biomarker research has identiﬁed several potential biomarkers of
healthy ageing, such as glucose and free triiodothyronine (fT3) serum
levels, CDKN2A (p16) gene expression, leukocyte telomere length
(LTL), and gait speed (Deelen et al., 2013; Njajou et al., 2009; Shiels,
2010). Some of these potential biomarkers of healthy ageing have
been reported to associate with mortality, while others show a cross-
sectional difference between young and old individuals, and therefore
seem useful. However, previous studies for biomarkers of healthy age-
ing did not yet consistently investigate all four criteria or the studied
biomarkers did not meet all criteria (e.g. LTL met three of the criteria,
but was unable to discriminate individuals based on their familial pro-
pensity for longevity (Deelen et al., 2014b)). Identiﬁed biomarkers
may be studied in GWAS with a larger sample size than GWAS for lon-
gevity. A similar approach has previously been applied in studies of
complex diseases, such as type 2 diabetes and Alzheimer's disease, in
which GWAS on endophenotypes successfully identiﬁed loci that play
a role in progresses underlying these diseases (Cruchaga et al., 2013;
Ingelsson et al., 2010). Hence, wewill apply the same approach to iden-
tify loci contributing to human longevity.
In this study, we ﬁrst test whether all available serum parameters in
the Leiden Longevity Study (LLS) (Schoenmaker et al., 2006) meet the
four criteria for a biomarker of healthy ageing. The LLS consists of 421
long-lived families (two generations), which have been followed for
over 10 years. This enables us to test potential biomarkers for their asso-
ciationwithmortality in two generations, i.e. the nonagenarians and the
combined group of their offspring and controls. In addition, we will com-
pare the levels of potential biomarkers between middle-aged members of
long-lived families and controls. We previously showed that long-lived
family members display a decreased prevalence of age-related diseases in
comparison to controls (Westendorp et al., 2009; Bos et al., 2013). Hence,
they are considered “healthy agers”. Subsequently, we tested whether
there is a signiﬁcant enrichmentof genetic loci contributing to the identiﬁed
biomarkers of healthy ageing in aGWAS for human longevity in individuals
of European descent, which is currently the largest GWAS for human lon-
gevity that has been performed (Deelen et al., 2014a).2. Materials and methods
2.1. Study population
The LLS consists of 421 long-lived families of European descent.
Families were included if at least two long-lived siblings were aliveBox 1
Biomarkers of healthy ageing
A biomarker of healthy ageing essentially (1) shows a changewith
chronological age, (2) discriminates individuals based on their fa-
milial propensity for longevity, and associates with (3) known
health parameters and (4) morbidity and/or mortality in prospec-
tive studies (Deelen et al., 2013). Ideally, the measurement of a
biomarker (of healthy ageing) should be inexpensive, fast, and
show minimal methodological variation within and between labo-
ratories (Martin-Ruiz and von, 2014).
There are three major classes of biomarkers of healthy ageing;
(1) the pro-longevity class, for which a high level is considered
healthy, (2) the anti-longevity class, for which a low level is consid-
ered healthy, and (3) the role-switching class, for which a level is
considered anti-longevity at middle age and pro-longevity at ad-
vanced age, or vice versa (Moeller et al., 2014).and fulﬁlled the age criterion of 89 years or older for males and
91 years or older for females, representing b0.5% of the Dutch popula-
tion in 2001 (Schoenmaker et al., 2006). In total, 944 long-lived proband
siblings (mean age= 94 years, range= 89–104), 1671 offspring (mean
age= 61 years, range= 39–81) and 744 spouses thereof (mean age=
60 years, range=36–79)were included. In the LLS, the spouses are con-
sidered controls. DNA from the LLSwas extracted fromwhite blood cells
at baseline using conventional methods (Beekman et al., 2006) and
genotyping was performed with Illumina Human660W-Quad and
OmniExpress BeadChips (Illumina, San Diego, CA, USA) (Deelen et al.,
2014a). In this study,we only used the individuals forwhich the identity
was conﬁrmed after genotyping.2.2. Biochemical measurements
All standard serum measurements were performed in non-fasting
venous blood samples using fully automated equipment.
Glucose, fructosamine, high-sensitivity C-reactive protein (CRP),
free fatty acids (FFA), triglyceride, and total and high-density lipopro-
tein (HDL) cholesterol levels were measured on the Hitachi Modular P
800. fT3, free thyroxine (fT4), and thyroid stimulating hormone (TSH)
levelsweremeasured on theModular E170,while parathyroid hormone
(PTH) and 25(OH) vitamin D3 were measured on the Cobas e 411 ana-
lyzer (all from Roche, Almere, the Netherlands) (Noordam et al., 2012;
Rozing et al., 2009; Rozing et al., 2010; Rozing et al., 2011). LDL choles-
terol levels were calculated using the Friedewald formula (Friedewald
et al., 1972) and set to missing if plasma triglyceride levels exceeded
4.52 mmol/L.
Insulin, insulin-like growth factor 1 (IGF-1), and insulin-like growth
factor-binding protein 3 (IGFBP3) levels were measured on the
Immulite 2500 (DPC, Los Angeles, CA, USA) (Rozing et al., 2009). For cal-
culation of the IGF-1/IGFBP3molar ratiowe used the following formula:
IGF−1=IGFBP3 molar ratio ¼ IGF−1 ng=mlð Þ  0:130=IGFBP3 ng=mlð Þ  0:036
Triglyceride levels and low-density lipoprotein (LDL) and high-
density lipoprotein (HDL) particle sizes and concentrations were mea-
sured using proton nuclear magnetic resonance (NMR) spectroscopy
(LipoScience Inc., Raleigh, NY, USA) (Vaarhorst et al., 2011).
Apolipoprotein E (ApoE), adiponectin (R&D Systems Europe, Ltd,
Abingdon, United Kingdom), leptin (Diagnostics Biochem Canada Inc.,
Dorchester, Canada), and interleukin 6 (IL-6) levels (Sanquin Reagents,
Amsterdam, The Netherlands) were determined using speciﬁc sand-
wich enzyme-linked immunosorbent assay (ELISA) (van Vlijmen et al.,
1994; Mooijaart et al., 2006; Stijntjes et al., 2013).
Alanine aminotransferase (ALAT) and aspartate aminotransferase
(ASAT) levels were measured using the NADH (with P-5′-P) methodol-
ogy, albumin levels using the Bromcresol Purple methodology, and
gamma-glutamyl transferase (γ-GT) levels using the L-gamma-
glutamyl-3-carboxy-4-nitroanilide substrate methodology (Sala et al.,
2014).
Creatine, folate and vitamin B12 levelsweremeasured on the Abbott
ci8200 (Architect, Abbott Laboratories, Illinois, USA), homocysteine
levels were measured using a competitive immunoassay (Architect),
while dehydroepiandrosterone sulfate (DHEAS) levels were measured
with a delayed one-step immunoassay (Architect) (Wijsman et al.,
2011).
For glucose, insulin, TSH, CRP, IL-6, FFA, triglyceride, ApoE,
adiponectin, leptin, PTH, 25(OH) vitamin D, ALAT, albumin, ASAT, γ-
GT, folate, vitamin B12, and DHEAS levels natural log transformed
values were used for analyses due to non-normal distribution of the
data, while triglyceride levels and LDL and HDL particle concentrations
were batch corrected before analysis (Vaarhorst et al., 2011).
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2.3.1. Change with chronological age
To determine the change of serum parameters with chronological
age, linear regression with the quantitative parameter as outcome, ad-
justed for gender, was performed in the combined group of LLS off-
spring and controls (n= 2342).
2.3.2. Discrimination based on familial propensity for longevity
To determine whether the serum parameters discriminate individ-
uals based on their familial propensity for longevity and group (i.e. off-
spring of nonagenarian or control) as tested variable, linear regression
with the quantitative biomarkers as outcome, adjusted for age, gender,
and their interaction, was performed in the LLS offspring and controls.
2.3.3. Association with general health
To determine the effect of the serum parameters on general practi-
tioner (GP)-reported general health, ordered logistic regression with
GP-reported general health as outcome, adjusted for age and gender,
was performed in the LLS offspring and controls. GP-reported general
health was coded as 1 (excellent), 2 (good), 3 (poor), or 4 (very poor).
2.3.4. Association with mortality
To determine the effect of the serum parameters on mortality, pro-
spective analysis with all-cause mortality as outcome, adjusted for ageTable 1
Characteristics of the measured serum parameters in the Leiden Longevity Study.
Parameter Controls
n Mean (SD)
Age, years 740 58.8 (7.5)
Female, n (%) 425 (57.4) NA
Use of lipid-lowering medication, n (%) 99 (14.8) NA
Use of antihypertensive medication, n (%) 180 (26.8) NA
Use of thyroid medication, n (%) 19 (2.8) NA
Glucose, mmol/L 726 6.1 (1.8)
Insulin, mU/L 706 25.0 (24.5)
Fructosamine, mmol/L 724 231.6 (36.8)
IGF-1, nmol/L 724 17.2 (5.1)
IGFBP3, mg/L 724 4.4 (0.9)
IGF-1/IGFBP3, molar ratio 724 10.7 (2.5)
Free triiodothyronine, pmol/L 724 4.1 (0.8)
Free thyroxine, pmol/L 724 15.3 (2.5)
Thyroid stimulating hormone, mU/L 721 2.1 (2.9)
C-reactive protein, mg/L 722 3.2 (11.2)
Interleukin 6, pg/mL 721 0.7 (1.9)
Free fatty acids, mmol/L 724 0.3 (0.2)
Triglycerides, NMR, mg/dL 722 179.8 (100.5)
Triglycerides, mmol/L 724 1.9 (1.4)
Total cholesterol, mmol/L 724 5.6 (1.1)
HDL cholesterol, mmol/L 723 1.4 (0.5)
LDL cholesterol, mmol/L 696 3.4 (0.9)
LDL size, nm 722 21.1 (0.8)
HDL size, nm 722 9.0 (0.5)
LDL particles, nmol/L 722 1395.0 (537.0)
HDL particles, μmol/L 722 32.5 (8.1)
Apolipoprotein E, mg/dL 723 2.9 (1.0)
Adiponectin, mg/L 714 6.1 (3.3)
Leptin, ng/mL 723 21.9 (23.6)
Parathyroid hormone, pg/mL 725 39.2 (12.1)
25(OH) vitamin D, nmol/L 725 71.9 (26.0)
Alanine aminotransferase, U/L 718 24.5 (15.5)
Albumin, g/L 725 43.3 (3.2)
Aspartate aminotransferase, U/L 725 27.4 (12.7)
Gamma-glutamyl transferase, U/L 726 31.9 (37.8)
Creatinine, mmol/L 727 82.0 (13.4)
Folate, nmol/L 713 10.5 (6.2)
Homocysteine, μmol/L 595 12.7 (3.8)
Vitamin B12, pmol/L 712 359.6 (145.9)
Dehydroepiandrosterone sulfate, μmol/L 678 4.4 (2.8)
SD; standard deviation, IGF-1; insulin-like growth factor 1, IGFBP3; insulin-like growth factor
available.(middle age only) and gender, was performed in the combined group
of LLS offspring and controls and separately in the LLS nonagenarians.
After a mean follow-up time of 7.6 years (LLS offspring and controls)
and 9.5 years (LLS nonagenarians), 4.6% (n = 108 (LLS offspring and
controls)) and 92.7% (n= 862 (LLS nonagenarians)) of the individuals
had died. We used a left-truncated Cox proportional hazards model to
adjust for late entry into the data set according to age. It should be
noted that not all serum parameters were available in the LLS
nonagenarians.
2.3.5. GWAS-identiﬁed genetic variants
To determine the effect of biomarker of healthy ageing-associated
genetic variants on human longevity, we performed a look-up of single
nucleotide polymorphisms (SNPs) in the largest GWAS for human lon-
gevity reported to date (Deelen et al., 2014a). SNPswere selected for the
look-up if they showed a P b 5 × 10−8 in the largest GWAS thus far per-
formed for the identiﬁed biomarkers of healthy ageing.We subsequent-
ly determined if there was an enrichment of these genome-wide
signiﬁcant SNPs in the longevity GWAS dataset.
Analyses were performed using STATA/SE 11.2 (StataCorp LP, Col-
lege Station, TX, USA). P-values were calculated using robust standard
errors to account for sibship relations. For all analyses, P-values b 0.05
were considered nominal signiﬁcant. After Bonferroni adjustment for
the number of independent variables (estimated with matSpDOffspring Nonagenarians
n Mean (SD) n Mean (SD)
1602 59.4 (6.5) 930 93.4 (2.6)
857 (53.5) NA 582 (62.6) NA
118 (8.3) NA NA NA
252 (17.7) NA NA NA
33 (2.3) NA NA NA
1568 5.8 (1.3) 858 6.6 (2.0)
1513 21.8 (19.7) 837 28.6 (25.4)
1558 229.9 (33.2) 850 238.4 (31.6)
1558 17.4 (5.2) 849 10.8 (4.2)
1558 4.3 (0.9) 848 3.0 (0.9)
1558 10.9 (2.5) 840 9.9 (2.6)
1558 4.1 (0.7) 850 4.1 (0.7)
1558 15.2 (2.4) 850 16.1 (2.7)
1552 2.0 (2.2) 848 2.3 (4.3)
1553 3.1 (10.7) 846 6.6 (13.8)
1550 0.6 (1.2) NA NA
1559 0.3 (0.2) 850 0.2 (0.2)
1555 167.9 (90.6) 844 147.7 (87.8)
1559 1.8 (1.1) NA NA
1559 5.6 (1.2) NA NA
1559 1.5 (0.4) NA NA
1524 3.3 (1.0) NA NA
1555 21.2 (0.8) 845 21.5 (0.8)
1555 9.1 (0.5) 845 9.3 (0.6)
1555 1321.6 (484.6) 844 1199.9 (434.3)
1555 32.1 (7.7) 844 26.4 (6.6)
1559 2.9 (1.0) 848 3.5 (1.2)
1548 6.4 (3.2) NA NA
1561 19.8 (21.4) NA NA
1557 39.5 (12.9) NA NA
1561 67.9 (24.5) NA NA
1547 25.0 (14.5) NA NA
1563 43.1 (2.9) NA NA
1561 27.2 (9.5) NA NA
1562 30.6 (34.5) NA NA
1563 81.3 (12.3) NA NA
1546 10.5 (6.1) NA NA
1250 12.6 (3.2) NA NA
1546 367.3 (143.6) NA NA
1468 4.5 (2.8) NA NA
-binding protein 3, LDL; low-density lipoprotein, HDL; high-density lipoprotein, NA; not
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(VeffLi = 27) was considered signiﬁcant.
3. Results
The characteristics of the individuals from the LLS that were used in
this study are shown in Table 1. The study population consists of long-
lived siblings, their offspring, which are genetically enriched for the pro-
pensity for longevity, and controls. For the analyses in this study, we
used 930 nonagenarians, 1602 offspring, and 740 controls.
3.1. Identiﬁcation of biomarkers of healthy ageing meeting all four criteria
Using the LLS, we veriﬁed for 35 serumparameters routinely used in
the clinic (see Table 1 for baseline characteristics) whether theymet the
four previously proposed criteria for biomarkers of healthy ageing
(Deelen et al., 2013) (Materials and methods section 2.3.1–2.3.4 and
Tables A.1–A.5). We identiﬁed three serum parameters meeting all
four criteria for a biomarker of healthy ageing in the LLS; glucose, insu-
lin, and (NMR-measured) triglycerides (Fig. 1 and Table 2). For glucose
and insulin, the direction of the observed associationsmatches between
the different criteria and both parameters seem to be anti-longevity bio-
markers, i.e. a low level is considered healthy. Triglycerides, on the other
hand, seems to be a role-switching biomarker, i.e. anti-longevity at mid-
dle age and pro-longevity at advanced age (Table 2).
3.2. Association of GWAS-identiﬁed genetic variants with human longevity
Next, we determinedwhether the identiﬁed biomarkers can be used
in GWAS to identify genetic loci underlying human longevity. For all
three parameters, we selected the SNPs that have previously been asso-
ciated with the serum levels of these parameters at a genome-wide sig-
niﬁcant level in the largest available GWAS for that trait (Scott et al.,
2012; Willer et al., 2013). We subsequently performed a look-up of
the selected genome-wide signiﬁcant SNPs (n = 91) in the largestFig. 1. Overlap between serum parameters signiﬁcantly associated with thGWAS for longevity reported to date (Deelen et al., 2014a) andobserved
an enrichment of signiﬁcant SNPs in our data (λ=1.92, Fig. 2), i.e. 17 of
the SNPs show a nominal signiﬁcant association with longevity
(P b 0.05, Table 3), whereas 4 signiﬁcant SNPs should be expected by
chance. This corresponds to an odds ratio of 0.232 (95% CI 0.136–
0.421, P= 3.07 × 10−6), based on 125,445 SNPs (out of the 2,470,845
tested) being nominal signiﬁcant (P b 0.05) in the longevity GWAS
dataset. One of these SNPs, rs4420638, representing the well-known
TOMM40/APOE/APOC1 locus, was still signiﬁcant after Bonferroni ad-
justment for multiple testing (P = 4.09 × 10−21). This locus is one of
the three loci previously associated with longevity at a genome-wide
signiﬁcant level, which shows the potential strength of our approach.
4. Discussion
By testing the four previously proposed criteria for biomarkers of
healthy ageing (Deelen et al., 2013) in individuals from the LLS, we
identiﬁed parameters involved in carbohydrate (glucose and insulin)
and lipid metabolism (triglycerides) as biomarkers of healthy ageing.
In addition, we showed that a relatively high proportion of the genetic
variants previously associated with these parameters are also nominal
signiﬁcant in the largest GWAS for human longevity to date (Deelen
et al., 2014a).
All three biomarkers of healthy ageing identiﬁed in our study have
previously been associated with at least one of the four criteria in
other populations (Murray et al., 2013; Liu et al., 2013; Martin-Ruiz
et al., 2011; Pyorala et al., 2000; Lara et al., 2015). This further supports
these parameters as biomarkers of healthy ageing. The proof of principle
for our approach could be nicely demonstrated, since the identiﬁed bio-
markers of healthy ageing had already beenmeasured in many popula-
tions with genetic data, which allowed large GWAS to identify genetic
loci associated with these parameters. However, even in the largest
GWAS for these parameters to date the explained variance is only 4.8%
(glucose), 1.2% (insulin) (Scott et al., 2012) and 2.1% (triglycerides)
(Willer et al., 2013), indicating that there is still a lot to discover.e biomarker of healthy ageing criteria in the Leiden Longevity Study.
Fig. 2.Quantile-quantile plot of the expected versus (unadjusted) observedΧ2 values in the largest genome-wide association study for longevity to date (Deelen et al., 2014a) for the single
nucleotide polymorphisms that showed a nominal signiﬁcantly association (P b 0.05) with glucose, insulin (Scott et al., 2012), and/or triglycerides (Willer et al., 2013). The shaded region
represents the 95% conﬁdence band. The red dotted line indicates the threshold for nominal signiﬁcance (P b 0.05).
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variants previously indicated to be involved in glucose, insulin and tri-
glycerides regulation in the longevity GWAS dataset. This indicates
that the genetic component underlying these traits may also contribute
to human longevity.
Eight of the studied genetic loci are associated with multiple traits
(Table 3), indicating that the identiﬁed biomarkers may share genetic
pathways underlying healthy ageing. Interestingly, four of these loci,
i.e. IRS1, RSPO3, TCF7L2, and FADS1-3, also showed a nominal signiﬁcant
association with longevity (P b 0.05). The FADS1-3 locus comprises 3
genes, FADS1, FADS2, and FADS3, which show a high sequence similarity
and are thus likely arisen through gene duplication during evolution
(Marquardt et al., 2000). The genetic variants associated with glucose
and triglycerides, i.e. rs174576 and rs174546, show cis-eQTL effects on
FADS2 in blood, heart left ventricle, and esophagus muscularis, accord-
ing to GTEx (http://www.gtexportal.org/home/). This indicates that
the FADS2 gene may be the most important gene at the FADS1-3 locus
concerning regulation of glucose and triglyceride levels and, potentially,
healthy ageing. Genetic variation at the IRS1, RSPO3, TCF7L2, and FADS1-
3 loci has also been associated with a range of metabolites, including
fatty acid levels, but also with clinical phenotypes and diseases, such
aswaist-to-hip ratio, bonemineral density, resting heart rate, type 2 di-
abetes, andmetabolic syndrome (http://www.ebi.ac.uk/gwas/) (Welter
et al., 2014). Hence, these loci seem to be important regulators of overall
metabolism.
Wehave to acknowledge that there are some limitations of using the
LLS to test all four criteria for a biomarker of healthy ageing. First, the
age range in the LLS is limited due to the family-based design of the
study, so the effects of a potential biomarker of healthy ageing below
50 years and between 70 and 90 years could not be determined. Second,
the number of deceased individuals in the group of middle-aged off-
spring and controls is limited, although it was large enough to show asigniﬁcant association of multiple parameters, including insulin, with
mortality. In addition, we were able to test the association of most of
the parameters with mortality in the long-lived individuals. Most of
our ﬁndings were also supported by previous studies, which shows
that the above mentioned limitations had limited effect on our results.
To test all four criteria for a biomarker of healthy ageing in one study,
the most optimal study design would be a population-based study in
which a large group of families is followed during their entire lifetime
and examined at multiple time points. However, since such a study is
not yet available, the LLS may be used as an alternative.
In conclusion, we showed, by a proof of principle study, that param-
eters involved in carbohydrate (glucose, insulin) and lipid metabolism
(triglycerides) are biomarkers of healthy ageing. The genetic loci associ-
ated with these parameters may be used in future studies in humans
and animal models to identify mechanisms that promote healthy
ageing.
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Table 2
Results of the tested serum parameters for the different criteria for biomarkers of healthy ageing.
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Table 3
Association of glucose-, insulin-, and triglyceride-associated genetic variants with survival to ages N90 years.
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